Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) just unveiled an announcement.
Cizzle Biotechnology Holdings PLC has announced significant progress in the commercial rollout of its CIZ1B biomarker test for early lung cancer detection in North America. Through its exclusive licensing partner, Cizzle Bio Inc, the test is being validated with Omni Health Diagnostics, a CLIA-certified laboratory, as part of a national expansion strategy. This partnership aims to provide nationwide testing capability across multiple states, with the test expected to complete CLIA accreditation soon. The collaboration is part of a broader strategy to meet anticipated market demand and improve early cancer detection, potentially reducing premature cancer deaths and enhancing patient survival rates. Additionally, Cizzle Bio Inc continues to make advance royalty payments, supporting Cizzle Biotechnology’s cash flow and demonstrating commitment to the partnership.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer that specializes in early cancer detection tests. The company has developed the CIZ1B biomarker test, a non-invasive and cost-effective blood test for early-stage lung cancer detection. Cizzle has entered into commercial royalty-bearing licensing agreements and collaborations with cancer care centers, and was listed on the London Stock Exchange in May 2021.
Average Trading Volume: 1,294,962
Technical Sentiment Signal: Hold
Current Market Cap: £7.14M
Learn more about CIZ stock on TipRanks’ Stock Analysis page.